| Title |
Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
|
|---|---|
| Published in |
OncoTargets and therapy, September 2016
|
| DOI | 10.2147/ott.s97746 |
| Pubmed ID | |
| Authors |
Pankit Vachhani, Hongbin Chen |
| Abstract |
Immunotherapy with immune checkpoint inhibitors has opened a new arena in cancer therapeutics. Pembrolizumab is a highly selective anti-programmed cell death protein 1 (PD-1) antibody that has shown efficacy, leading to survival benefit and durable responses, in some patients with non-small cell lung cancer (NSCLC). It has been approved by the US Food and Drug Administration for the treatment of patients with metastatic NSCLC, whose tumors express PD-1 ligand 1 (PD-L1), with disease progression on or after platinum-containing chemotherapy. Here, we briefly discuss the PD-1/PD-L1 pathway and pembrolizumab before delving into the clinical trials that have led to its just-mentioned approval in NSCLC and ongoing clinical trials. Finally, we discuss the use of biomarkers, primarily PD-L1, in the context of pembrolizumab and NSCLC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 64 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 22% |
| Other | 8 | 13% |
| Researcher | 7 | 11% |
| Student > Doctoral Student | 6 | 9% |
| Student > Master | 6 | 9% |
| Other | 12 | 19% |
| Unknown | 11 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 33% |
| Biochemistry, Genetics and Molecular Biology | 7 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 9% |
| Agricultural and Biological Sciences | 4 | 6% |
| Neuroscience | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 17 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 February 2021.
All research outputs
#7,960,512
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#430
of 3,016 outputs
Outputs of similar age
#115,566
of 348,371 outputs
Outputs of similar age from OncoTargets and therapy
#14
of 86 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,371 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.